Vita Imaging develops AURA™, a non-invasive imaging and spectroscopy system utilizing Raman technology for the rapid detection of pre-cancerous and malignant skin lesions, providing results in under 1.5 seconds. This technology addresses the critical need for early and accurate skin cancer diagnosis, significantly improving patient outcomes and survival rates.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing skin cancer often relies on biopsies, which are invasive, time-consuming, and can lead to scarring. Current methods may also delay the detection of early-stage malignancies, impacting treatment outcomes and survival rates.
Solution
Vita Imaging's AURA™ system offers a non-invasive alternative for the rapid detection of pre-cancerous and malignant skin lesions. Utilizing Raman spectroscopy, AURA™ analyzes the molecular composition of skin tissue to identify cancerous changes in under 1.5 seconds. The technology aims to provide physicians with a tool for faster and more accurate screening, facilitating earlier diagnosis and treatment of skin cancer. By eliminating the need for traditional biopsies in many cases, AURA™ can reduce patient discomfort, minimize scarring, and accelerate the diagnostic process. The device is currently undergoing FDA review, with market clearance anticipated in the first half of 2025.
Target Audience
The primary target audience includes dermatologists, oncologists, and other healthcare professionals involved in skin cancer screening and diagnosis.
Features
- Non-invasive Raman spectroscopy for real-time analysis of skin lesions
- Rapid results in under 1.5 seconds, enabling quick screening during consultations
- Designed to aid in the early detection of both pre-malignant and malignant skin cancers
- Aims to reduce the need for invasive biopsies